Nationwide Coverage and Cost-Sharing for PCSK9 Inhibitors Among Medicare Part D Plans
Open Access
- 1 October 2017
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 2 (10) , 1164-1166
Abstract
Approximately 9 million US adults with atherosclerotic cardiovascular disease or familial hypercholesterolemia do not achieve optimal levels of low-density lipoprotein cholesterol despite maximally tolerated statin therapy.1 Adding a proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) may significantly lower low-density lipoprotein cholesterol levels and reduce the risk of myocardial infarction and stroke.2 However, PCSK9is are expensive, with annual costs exceeding $14 500.1 Understanding patients’ share of drug costs is important because high out-of-pocket costs can adversely affect affordability and adherence to lifelong treatment.3 Because 1 in 4 Medicare beneficiaries has ischemic heart disease and nearly 1 in 2 has hyperlipidemia,4 we examined PCSK9i cost-sharing requirements for Medicare Part D plans nationwide, which insure 41 million beneficiaries.5Keywords
This publication has 4 references indexed in Scilit:
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseNew England Journal of Medicine, 2017
- Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular DiseaseJAMA, 2016
- Specialty Pharmaceuticals for Hyperlipidemia — Impact on Insurance PremiumsNew England Journal of Medicine, 2015
- Cost-related Nonadherence by Medication Type Among Medicare Part D Beneficiaries With DiabetesMedical Care, 2013